Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Squamous Cell Carcinoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...